|
1
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hariharan D, Saied A and Kocher HM:
Analysis of mortality rates for pancreatic cancer across the world.
HPB Oxf. 10:58–62. 2008. View Article : Google Scholar
|
|
3
|
Sener SF, Fremgen A, Menck HR and
Winchester DP: Pancreatic cancer: A report of treatment and
survival trends for 100,313 patients diagnosed from 1985–1995,
using the National Cancer Database. J Am Coll Surg. 189:1–7. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simard EP, Ward EM, Siegel R and Jemal A:
Cancers with increasing incidence trends in the United States: 1999
through 2008. CA Cancer J Clin. 62:118–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petersen GM, de Andrade M, Goggins M,
Hruban RH, Bondy M, Korczak JF, Gallinger S, Lynch HT, Syngal S,
Rabe KG, et al: Pancreatic cancer genetic epidemiology consortium.
Cancer Epidemiol Biomarkers Prev. 15:704–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blackford A, Parmigiani G, Kensler TW,
Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ,
Eshleman JR, et al: Genetic mutations associated with cigarette
smoking in pancreatic cancer. Cancer Res. 69:3681–3688. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi C, Hruban RH and Klein AP: Familial
pancreatic cancer. Arch Pathol Lab Med. 133:365–374.
2009.PubMed/NCBI
|
|
9
|
American Cancer Society. American cancer
society. Cancer Facts & Figures. 2013, http://www.cancer.org/research/cancer-factsstatistics/cancerfactsfigures2013/.
Access date: June 23rd, 2015
|
|
10
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sheridan MB, Ward J, Guthrie JA, Spencer
JA, Craven CM, Wilson D, Guillou PJ and Robinson PJ: Dynamic
contrast-enhanced MR imaging and dual-phase helical CT in the
preoperative assessment of suspected pancreatic cancer: A
comparative study with receiver operating characteristic analysis.
AJR Am J Roentgenol. 173:583–590. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Horton KM and Fishman EK: Adenocarcinoma
of the pancreas: CT imaging. Radiol Clin North Am. 40:1263–1272.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faria SC, Tamm EP, Loyer EM, Szklaruk J,
Choi H and Charnsangavej C: Diagnosis and staging of pancreatic
tumors. Semin Roentgenol. 39:397–411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
House MG, Yeo CJ, Cameron JL, Campbell KA,
Schulick RD, Leach SD, Hruban RH, Horton KM, Fishman EK and
Lillemoe KD: Predicting resectability of periampullary cancer with
three-dimensional computed tomography. J Gastrointest Surg.
8:280–288. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vachiranubhap B, Kim YH, Balci NC and
Semelka RC: Magnetic resonance imaging of adenocarcinoma of the
pancreas. Top Magn Reson Imaging. 20:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tellez-Avila FI, Chavez-Tapia NC,
López-Arce G, Franco-Guzmán AM, Sosa-Lozano LA, Alfaro-Lara R,
Chan-Nuñez C, Giovannini M, Elizondo-Rivera J and Ramírez-Luna MA:
Vascular invasion in pancreatic cancer: Predictive values for
endoscopic ultrasound and computed tomography imaging. Pancreas.
41:636–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Warshaw AL, Tepper JE and Shipley WU:
Laparoscopy in the staging and planning of therapy for pancreatic
cancer. Am J Surg. 151:76–80. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sperti C, Pasquali C, Bissoli S,
Chierichetti F, Liessi G and Pedrazzoli S: Tumor relapse after
pancreatic cancer resection is detected earlier by 18-FDG PET than
by CT. J Gastrointest Surg. 14:131–140. 2010. View Article : Google Scholar
|
|
19
|
Rubin P and Carter SK: Combination
radiation therapy and chemotherapy: A logical basis for their
clinical use. CA Cancer J Clin. 26:274–292. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bilimoria KY, Bentrem DJ, Ko CY, Ritchey
J, Stewart AK, Winchester DP and Talamonti MS: Validation of the
6th edition AJCC Pancreatic Cancer Staging System: Report from the
National Cancer Database. Cancer. 110:738–744. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fidler IJ: The organ microenvironment and
cancer metastasis. Differentiation. 70:498–505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato N, Maehara N and Goggins M: Gene
expression profiling of tumor-stromal interactions between
pancreatic cancer cells and stromal fibroblasts. Cancer Res.
64:6950–6956. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato N, Fukushima N, Maehara N,
Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M:
SPARC/osteonectin is a frequent target for aberrant methylation in
pancreatic adenocarcinoma and a mediator of tumor-stromal
interactions. Oncogene. 22:5021–5030. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang RF, Moore T, Arumugam T,
Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB and Logsdon CD:
Cancer-associated stromal fibroblasts promote pancreatic tumor
progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hansel DE, Kern SE and Hruban RH:
Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum
Genet. 4:237–256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hruban RH, Maitra A and Goggins M: Update
on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol.
1:306–316. 2008.PubMed/NCBI
|
|
30
|
Pellegata NS, Sessa F, Renault B, Bonato
M, Leone BE, Solcia E and Ranzani GN: K-ras and p53 gene mutations
in pancreatic cancer: Ductal and nonductal tumors progress through
different genetic lesions. Cancer Res. 54:1556–1560.
1994.PubMed/NCBI
|
|
31
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maitra A and Hruban RH: Pancreatic cancer.
Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar
|
|
33
|
Caldas C, Hahn SA, da Costa LT, Redston
MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern
SE: Frequent somatic mutations and homozygous deletions of the p16
(MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:27–32. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schutte M, Hruban RH, Geradts J, Maynard
R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff
I, Schmiegel W, et al: Abrogation of the Rb/p16 tumor-suppressive
pathway in virtually all pancreatic carcinomas. Cancer Res.
57:3126–3130. 1997.PubMed/NCBI
|
|
35
|
Hahn SA, Hoque AT, Moskaluk CA, da Costa
LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ,
Hruban RH, et al: Homozygous deletion map at 18q21.1 in pancreatic
cancer. Cancer Res. 56:490–494. 1996.PubMed/NCBI
|
|
36
|
Yachida S, White CM, Naito Y, Zhong Y,
Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA,
Herman JM, et al: Clinical significance of the genetic landscape of
pancreatic cancer and implications for identification of potential
long-term survivors. Clin Cancer Res. 18:6339–6347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vonlaufen A, Phillips PA, Xu Z, Goldstein
D, Pirola RC, Wilson JS and Apte MV: Pancreatic stellate cells and
pancreatic cancer cells: An unholy alliance. Cancer Res.
68:7707–7710. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bissell MJ and Radisky D: Putting tumours
in context. Nat Rev Cancer. 1:46–54. 2001. View Article : Google Scholar
|
|
39
|
Heldin CH, Rubin K, Pietras K and Ostman
A: High interstitial fluid pressure - an obstacle in cancer
therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Neesse A, Michl P, Frese KK, Feig C, Cook
N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, et al:
Stromal biology and therapy in pancreatic cancer. Gut. 60:861–868.
2011. View Article : Google Scholar
|
|
41
|
Lunevicius R, Nakanishi H, Ito S, Kozaki
K, Kato T, Tatematsu M and Yasui K: Clinicopathological
significance of fibrotic capsule formation around liver metastasis
from colorectal cancer. J Cancer Res Clin Oncol. 127:193–199. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moir JA, Mann J and White SA: The role of
pancreatic stellate cells in pancreatic cancer. Surg Oncol.
24:232–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moinfar F, Man YG, Arnould L, Bratthauer
GL, Ratschek M and Tavassoli FA: Concurrent and independent genetic
alterations in the stromal and epithelial cells of mammary
carcinoma: Implications for tumorigenesis. Cancer Res.
60:2562–2566. 2000.PubMed/NCBI
|
|
44
|
Bachem MG, Schneider E, Gross H,
Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grünert A and
Adler G: Identification, culture, and characterization of
pancreatic stellate cells in rats and humans. Gastroenterology.
115:421–432. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Geerts A: History, heterogeneity,
developmental biology, and functions of quiescent hepatic stellate
cells. Semin Liver Dis. 21:311–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kanno A, Satoh K, Masamune A, Hirota M,
Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al:
Periostin, secreted from stromal cells, has biphasic effect on cell
migration and correlates with the epithelial to mesenchymal
transition of human pancreatic cancer cells. Int J Cancer.
122:2707–2718. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guweidhi A, Kleeff J, Adwan H, Giese NA,
Wente MN, Giese T, Büchler MW, Berger MR and Friess H: Osteonectin
influences growth and invasion of pancreatic cancer cells. Ann
Surg. 242:224–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Arnold SA and Brekken RA: SPARC: A
matricellular regulator of tumorigenesis. J Cell Commun Signal.
3:255–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chlenski A, Liu S, Crawford SE, Volpert
OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J,
et al: SPARC is a key Schwannian-derived inhibitor controlling
neuroblastoma tumor angiogenesis. Cancer Res. 62:7357–7363.
2002.PubMed/NCBI
|
|
50
|
Podhajcer OL, Benedetti LG, Girotti MR,
Prada F, Salvatierra E and Llera AS: The role of the matricellular
protein SPARC in the dynamic interaction between the tumor and the
host. Cancer Metastasis Rev. 27:691–705. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gundewar C, Sasor A, Hilmersson KS,
Andersson R and Ansari D: The role of SPARC expression in
pancreatic cancer progression and patient survival. Scand J
Gastroenterol. 50:1170–1174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gao J, Song J, Huang H, Li Z, Du Y, Cao J,
Li M, Lv S, Lin H and Gong Y: Methylation of the SPARC gene
promoter and its clinical implication in pancreatic cancer. J Exp
Clin Cancer Res. Mar 26–2010.29:28Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lunardi S, Muschel RJ and Brunner TB: The
stromal compartments in pancreatic cancer: Are there any
therapeutic targets? Cancer Lett. 343:147–155. 2014. View Article : Google Scholar
|
|
54
|
Gorantla B, Bhoopathi P, Chetty C,
Gogineni VR, Sailaja GS, Gondi CS and Rao JS: Notch signaling
regulates tumor-induced angiogenesis in SPARC-overexpressed
neuroblastoma. Angiogenesis. 16:85–100. 2013. View Article : Google Scholar
|
|
55
|
Komar G, Kauhanen S, Liukko K, Seppänen M,
Kajander S, Ovaska J, Nuutila P and Minn H: Decreased blood flow
with increased metabolic activity: A novel sign of pancreatic tumor
aggressiveness. Clin Cancer Res. 15:5511–5517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kindler HL, Niedzwiecki D, Hollis D,
Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF,
O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab
compared with gemcitabine plus placebo in patients with advanced
pancreatic cancer: Phase III trial of the Cancer and Leukemia Group
B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mantoni TS, Schendel RR, Rödel F,
Niedobitek G, Al-Assar O, Masamune A and Brunner TB: Stromal SPARC
expression and patient survival after chemoradiation for
non-resectable pancreatic adenocarcinoma. Cancer Biol Ther.
7:1806–1815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ting DT, Wittner BS, Ligorio M, Vincent
Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW,
Xega K, et al: Single-cell RNA sequencing identifies extracellular
matrix gene expression by pancreatic circulating tumor cells. Cell
Rep. 8:1905–1918. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar
|
|
62
|
Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng
T, Liu R, Bai M, Zhou LK, Zhang XY, et al: Change of SPARC
expression after chemotherapy in gastric cancer. Cancer Biol Med.
12:33–40. 2015.PubMed/NCBI
|
|
63
|
Neuzillet C, Tijeras-Raballand A, Cros J,
Faivre S, Hammel P and Raymond E: Stromal expression of SPARC in
pancreatic adenocarcinoma. Cancer Metastasis Rev. 32:585–602. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Seno T, Harada H, Kohno S, Teraoka M,
Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits
cell migration and invasion in malignant gliomas. Int J Oncol.
34:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL,
Ye QH, Qin LX and Wu XZ: microRNA-29a suppresses cell proliferation
by targeting SPARC in hepatocellular carcinoma. Int J Mol Med.
30:1321–1326. 2012.PubMed/NCBI
|
|
66
|
Zhou X, Tan FK, Guo X and Arnett FC:
Attenuation of collagen production with small interfering RNA of
SPARC in cultured fibroblasts from the skin of patients with
scleroderma. Arthritis Rheum. 54:2626–2631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Camino AM, Atorrasagasti C, Maccio D,
Prada F, Salvatierra E, Rizzo M, Alaniz L, Aquino JB, Podhajcer OL,
Silva M, et al: Adenovirus-mediated inhibition of SPARC attenuates
liver fibrosis in rats. J Gene Med. 10:993–1004. 2008. View Article : Google Scholar : PubMed/NCBI
|
